Theme: The seminar will introduce the audience to the biosynthetic production of cannabinoids, through fermentation in brewer’s yeast. The resultant products are pure, consistent and sustainable, and rare cannabinoids - present in trace amounts in the plant - can be readily produced at scale. Willow’s FutureGrown cannabigerol (CBG) will be introduced, demonstrating its potential as a “hero” active ingredient in skincare products.
Dr. Hickling has 25 years’ experience of production and business development in the pharmaceutical and biotech industries, having previously held roles at DSM, Codexis and PharmaZell. His focus has been on cutting-edge technologies in highly regulated markets. He received his B.Sc. (Hons) from Sheffield Hallam University, and Ph.D. from the University of Bath.
We use necessary cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. Using this tool will set a cookie on your device to remember your preferences. You are able to manage settings here and turn off analytical cookies: Cookie settingsACCEPT ANALYTICAL COOKIES
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.